Vandria SA

June is Alzheimer’s & Brain Awareness Month. At Vandria we are passionate about developing life changing therapies to treat age-related and chronic diseases, with a focus on neurological disorders. We are at the vanguard of mitochondrial therapeutics, developing first-in-class mitophagy inducers that rejuvenate cells. Our lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. It is on track to enter clinical trials this summer. Worldwide, more than 55 million people are living with Alzheimer's or another dementia. Join the Alzheimer's Association in going purple and raising awareness this June. The more that people know about Alzheimer's, the more action we inspire. Let’s End Alzheimer’s - #ENDALZ. If you’re intrigued by our science you can find out more about our portfolio at www.vandria.com #Alzheimers #ParkinsonsDisease #PD #MitochondrialTherapeutics #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation

Our CEO Klaus Dugi and Head of BD & Finance Peter Harboe-Schmidt are looking forward to attending BIO International Convention next week in San Diego 3-6 June. Plans are well advanced to start clinical trials for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer this summer and we are already planning our series B to fund further trials and pipeline growth. If you’d like to meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio HERE www.vandria.com #Partnering #investment #lifescienes #MitochonrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

This week we are highlighting Dementia Action Week 2024 organised by Alzheimer's Society, underlining our commitment to scientific innovation to find effective solutions to this disabling disease.   As a Swiss biotech start-up specialising in the development of advanced #mitophagy inducers, our mission is to rejuvenate cells to combat age-related and chronic diseases.   By understanding the disease and its early stages, and finding new therapies that might intervene earlier, we strive to create hope and improve the quality of life for those affected and their families.   Together, we seek to make a significant difference to the lives of people living with this #dementia and other #NeurodegenerativeDiseases.   To find out more, visit our website www.vandria.com   #DementiaActionWeek2024 #Biotech #Innovation #MedicalResearch #ScientificAdvancement

Lovely interview with our CEO Klaus Dugi - thank you Wani Baumgartner. Life sciences is built on strong relationships so its nice to get an insight into Klaus's career moves and motivations. Thank you for the opportunity to participate in your #CEO Q&A series. #leadership #teamwork #motivation #career

BIO International Convention is fast approaching. Our CEO Klaus Dugi and Head of BD & Finance Peter Harboe-Schmidt will be in in San Diego 3-6 June to catch up with colleagues from the life sciences and healthcare industry, and network with biotech and pharma industry colleagues and investors. Plans are well advanced to start clinical trials for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer this summer and we are already planning our series B to fund further trials and pipeline growth. If you’d like to meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio HERE www.vandria.com #Partnering #investment #lifescienes #MitochonrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

Our CEO Klaus Dugi was interviewed by Helen Albert for a feature in this month's Inside Precision Medicine on the exciting developments in new approaches to treat #Alzheimers. Read the full article here: https://lnkd.in/g4cKb6_C Our excerpt: Vandria is taking a completely different approach to treating Alzheimer’s disease. It is known that one feature of Alzheimer’s disease and other age-related neurodegeneration is an accumulation of damaged mitochondria in the brain. “There’s a highly selective process where the body has to identify damaged mitochondria, digest them and replace them with healthy mitochondria—a process called mitophagy, which seems to be impaired as we age particularly in certain disease populations,” explained Dugi. “What we’re trying to do with very selective and potent compounds is to induce this natural process of mitophagy to tackle various diseases, including Alzheimer’s disease.” The company is still at an early stage of drug development, but it has already seen some promising early results in animal models.

Looking forward to the premier biotechnology conference in the Swiss biotech calendar next week! Our CEO Klaus Dugi and Head of BD & Finance Peter Harboe-Schmidt will be in Basel 22-23 attending @Swiss Biotech #swissbiotechday. Attracting professionals from the global life sciences community, it provides a platform for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing. Klaus will be pitching the Vandria story and providing an update on our lead program. VNA-318 is a brain-penetrant, patent-protected mitophagy inducer for CNS diseases which is on track to enter clinical trials in Q2 this year. We are already planning our series B to fund further trials and pipeline growth. Come to our presentation in the Innovative Companies in Healthspan and Longevity session, 09.00 – 9.45 23 April, Room Rio. Our co-founder and chairman Patrick Aebischer is presenting during the Plenary Session 1 on the Panel on Longevity, Room Montreal To meet up send us an email at info@vandria.com More information on our science and portfolio at www.vandria.com #SwissBiotech #MitochonrialTherapeutics #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Partnering

On the 75th anniversary of the World Health Organization World Health Day we join with others to both celebrate the advances being made in improving healthcare worldwide, to recognize the challenges that remain, and promote the right to good health for all. #MyHealthMyRight Mitochondria are fundamental to life and impact the health of our cells. Vandria is at the vanguard of mitochondrial therapeutics developing novel medicines with potential across many disease areas, including age-related and chronic diseases. Capitalizing on 15 years of discovery science, we have a pipeline of first-in-class mitophagy inducers that help rejuvenate cells. Our lead candidate, VNA-318, is a brain-penetrant, patent-protected, #mitophagy inducer which has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of #NeuroDegenerativeDiseases such as #Alzheimer’s and #Parkinson’sDisease. VNA-318 is expected to enter the clinic this summer. More information on our science and portfolio HERE www.vandria.com #WorldHealthDay #MitochonrialTherapeutics #DrugDevelopment

Delighted to have featured in BioCentury Inc. with an #EmergingCompanyProfile. See the excellent write up by Danielle Golovin, Ph.D. https://lnkd.in/exK7pBHr (behind paywall). The article charts our excellent progress to restore functional mitochondria in various organs by inducing mitophagy. Our lead candidate VNA-318 will enter the clinic this summer in Europe with the first CNS indication being mild cognitive impairment. In addition, we have a pipeline of compounds that all hit the same molecular target with tailored chemical properties to target different tissues for different indications: VNA-052 is targeted to muscle, VNA-438 to the liver, and VNA-710 to the lung. Follow us to keep updated with our progress. #mitophagy #drugdevelopment

Delighted to have featured in BioCentury Inc. with an #EmergingCompanyProfile. See the excellent write up by Danielle Golovin, Ph.D. https://lnkd.in/exK7pBHr (behind paywall). The article charts our excellent progress to restore functional mitochondria in various organs by inducing mitophagy. Our lead candidate VNA-318 will enter the clinic this summer in Europe with the first CNS indication being mild cognitive impairment. In addition, we have a pipeline of compounds that all hit the same molecular target with tailored chemical properties to target different tissues for different indications: VNA-052 is targeted to muscle, VNA-438 to the liver, and VNA-710 to the lung. Follow us to keep updated with our progress. #mitophagy #drugdevelopment